Reply to A. Indini et al

J Clin Oncol. 2016 Mar 20;34(9):1018-9. doi: 10.1200/JCO.2015.65.7007. Epub 2016 Jan 19.

Affiliations

¹ Memorial Sloan Kettering Cancer Center, New York, NY.
² Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY.
³ Memorial Sloan Kettering Cancer Center; Ludwig Institute for Cancer Research; and Weill Cornell Medical College, New York, NY.
⁴ Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY [email protected].

PMID: 26786917
DOI: 10.1200/JCO.2015.65.7007

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal / adverse effects*
Antineoplastic Agents / adverse effects*
Female
Humans
Immunosuppressive Agents / therapeutic use*
Male
Melanoma / drug therapy*
Skin Neoplasms / drug therapy*

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Immunosuppressive Agents

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States